Reports
Sale
Global Antiviral Drugs Market Size, Share, Trends: By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others; By Type: Branded, Generics; By Application; By Dosage Form; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Antiviral Drugs Market Outlook
The global antiviral drugs market size attained a value of USD 55.17 billion in 2023 driven by rising prevalence of viral infections, coupled with the rising healthcare expenditure in the emerging economies. The market is anticipated to grow at a CAGR of 4.1% during the forecast period of 2024-2032 to attain a value of USD 79.21 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America Represents a Considerable Share of the Antiviral Drugs Industry
The antiviral drugs industry is driven by the rising prevalence of viral infections and the increasing research and development (R&D) of antiviral drugs. North America holds a considerable market share of this sector, which can be attributed to the presence of major companies in the region. The widespread access to standard medical services in the region is also surging the demand for antiviral drugs, which is bolstering the market growth. Moreover, the introduction of various favourable government initiatives in the region is driving the market for antiviral drugs. For instance, in July 2021, the United States government announced an investment of more than USD 3 billion in the American Rescue Plan to accelerate the discovery, development and manufacturing of antiviral medicines.
Meanwhile, the Asia Pacific region is expected to grow due to the robustly developing healthcare and the introduction of favourable government initiatives. With the increasing manufacturing capacity of the pharmaceuticals in India and China, the market is poised to witness rapid growth in the forecast period.
Antiviral Drugs: Market Segmentation
Antiviral drugs are medications that are used to treat viral diseases by either killing the virus present or inhibiting the virus from replicating and spreading. Antiviral drugs are typically used to treat specific viruses. Moreover, broad-spectrum antiviral drugs are effective against a wide range of viruses.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major drug classes of antiviral drugs are:
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
Based on type, the market is bifurcated into:
- Branded
- Generic
The market can be broadly categorised on the basis of its applications into:
- HIV
- Hepatitis
- Influenza
- Herpes
- Others
The EMR report looks into the regional markets of antiviral drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Challenges Associated with the Development of Antiviral Drugs to Hinder the Market Growth
The challenges associated with the development of antiviral drugs owing to mutations of viruses is hindering the market growth. Moreover, the development of antiviral drugs involves high investments, which is impeding the growth of the market. As the precise diagnosis of viral issues is difficult and the efficiency of antiviral drugs is limited to early treatment, the demand for antiviral drugs is reducing and obstructing the market growth.
As antiviral drugs have a narrow antiviral spectrum, their demand is reducing, which is negatively impacting the growth of the market. With the growing demand for alternative medicines such as naturopathy and homoeopathy, the market growth may witness a decline. The risk of toxic side effects from antiviral drugs is reducing their use and constraining the industry growth. The increasing ineffectiveness of antiviral drugs against latent viruses may impede the market growth in the forecast period.
Key Industry Players in the Global Antiviral Drugs Market
The report presents a detailed analysis of the following key players in the global antiviral drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc.
- AbbVie Inc.
- Merck and Co., Inc.
- Johnson and Johnson Services, Inc.
- Cipla Inc.
- Bristol-Myers Squibb Company
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories Ltd.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by Dosage Form |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Viral Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Viral Diseases Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Viral Disease Epidemiology (2016-2031)
5.3 Europe Viral Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Viral Disease Epidemiology (2016-2031)
5.5 Latin America Viral Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Viral Disease Epidemiology (2016-2031)
6 Global Antiviral Drugs Market Overview
6.1 Global Antiviral Drugs Market Historical Value (2017-2023)
6.2 Global Antiviral Drugs Market Forecast Value (2024-2032)
7 Global Antiviral Drugs Market Landscape
7.1 Antiviral Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Antiviral Drugs: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Type
7.2.3 Analysis by Application
7.2.4 Analysis by Dosage Form
7.2.5 Analysis by End User
7.2.6 Analysis by Distribution Channel
8 Global Antiviral Drugs Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Antiviral Drugs Market Segmentation
9.1 Global Antiviral Drugs Market by Drug Class
9.1.1 Market Overview
9.1.2 DNA Polymerase Inhibitors
9.1.3 Reverse Transcriptase Inhibitors
9.1.4 Protease Inhibitors
9.1.5 Neuraminidase Inhibitors
9.1.6 Others
9.2 Global Antiviral Drugs Market by Type
9.2.1 Market Overview
9.2.2 Branded
9.2.3 Generics
9.3 Global Antiviral Drugs Market by Application
9.3.1 Market Overview
9.3.2 HIV
9.3.3 Hepatitis
9.3.4 Influenza
9.3.5 Herpes
9.3.6 Others
9.4 Global Antiviral Drugs Market by Dosage Form
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Topical
9.4.4 Parenteral
9.5 Global Antiviral Drugs Market by End User
9.5.1 Market Overview
9.5.2 Hospitals
9.5.3 Homecare
9.5.4 Specialty Clinics
9.5.5 Others
9.6 Global Antiviral Drugs Market by Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacy
9.6.3 Retail Pharmacy
9.6.4 Online Pharmacy
9.7 Global Antiviral Drugs Market by Region
9.7.1 Market Overview
9.7.2 North America
9.7.3 Europe
9.7.4 Asia Pacific
9.7.5 Latin America
9.7.6 Middle East and Africa
10 North America Antiviral Drugs Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Antiviral Drugs Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Antiviral Drugs Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Antiviral Drugs Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Antiviral Drugs Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Gilead Sciences, Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 F. Hoffmann-La Roche AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 GlaxoSmithKline plc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Merck and Co., Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson and Johnson Services, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Cipla Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb Company
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Aurobindo Pharma Limited
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Dr. Reddy’s Laboratories Ltd.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Laurus Labs
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Amneal Pharmaceuticals
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Zydus Group
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
22 Antiviral Drugs - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, antiviral drugs market reached a value of USD 55.17 billion in 2023.
The market is projected to expand at a CAGR of 4.1% from 2024 to 2032, growing to USD 79.21 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the market include the rising prevalence of viral infections, coupled with the rising healthcare expenditure in the emerging economies.
The growing R&D activities aimed towards developing efficient and cost-effective antiviral drugs is expected to be a key trend guiding the growth of the industry.
The major drug classes available in the market are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and neuraminidase inhibitors, among others.
The different types of antiviral drugs are branded and generics.
The different applications of antiviral drugs are HIV, hepatitis, influenza, and herpes, among others.
The major players in the industry are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie Inc., Merck and Co., Inc., Johnson and Johnson Services, Inc., Cipla Inc., Bristol-Myers Squibb Company, Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories Ltd., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER